Moleculin Biotech
MBRX
14 hedge funds and large institutions have $1.1M invested in Moleculin Biotech in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
0.08% more ownership
Funds ownership: 0.46% → 0.54% (+0.08%)
7% less funds holding
Funds holding: 15 → 14 (-1)
28% less capital invested
Capital invested by funds: $1.53M → $1.1M (-$425K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$156K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$42.2K |
| 3 |
AC
Armistice Capital
New York
|
+$34.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIM
FWL Investment Management
Dallas,
Texas
|
-$1.64K |
| 2 |
NS
NBC Securities
Birmingham,
Alabama
|
-$1K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$231 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$112 |
| 5 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$6 |
MBRX Hedge Fund Activity: Q2 2024 in Review
14 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2024, worth a combined $1.1M — down 28% from $1.53M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of MBRX and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.
The largest buyer was LPL Financial, opening a new position worth an estimated $156K. The largest seller was FWL Investment Management, exiting entirely with an estimated $1.64K sold.
- 14 institutional investors held Moleculin Biotech (MBRX) as of Q2 2024, down from 15 in Q1 2024.
- Funds reported $1.1M of Moleculin Biotech stock for Q2 2024, down 28% quarter-over-quarter.
- 2 funds opened new Moleculin Biotech positions in Q2 2024 and 3 closed out, a net change of -1 holder.
- The largest Moleculin Biotech buyer in Q2 2024 was LPL Financial, an estimated $156K added.
- The largest Moleculin Biotech seller in Q2 2024 was FWL Investment Management, an estimated $1.64K sold.
Based on aggregated 13F filings for Q2 2024.